The ATNM chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ATNM chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ATNM stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
View ATNM Detailed Price Forecast - CNN Money | View ATNM Detailed Summary - Google Finance | ||
View ATNM Detailed Summary - Yahoo! Finance | View ATNM Stock Research & Analysis - Zacks.com |
View ATNM Trends & Analysis - Trade-Ideas | View ATNM Major Holders - Barrons | ||
View ATNM Call Transcripts - NASDAQ | View ATNM Breaking News & Analysis - Seeking Alpha | ||
View ATNM Annual Report - CompanySpotlight.com | View ATNM OTC Short Report - OTCShortReport.com | ||
View ATNM Fundamentals - TradeKing | View ATNM SEC Filings - Bar Chart | ||
View Historical Prices for ATNM - The WSJ | View Performance/Total Return for ATNM - Morningstar | ||
View the Analyst Estimates for ATNM - MarketWatch | View the Earnings History for ATNM - CNBC | ||
View the ATNM Earnings - StockMarketWatch | View ATNM Buy or Sell Recommendations - MacroAxis | ||
View the ATNM Bullish Patterns - American Bulls | View ATNM Short Pain Metrics - ShortPainBot.com |
View ATNM Stock Mentions - StockTwits | View ATNM Stock Mentions - PennyStockTweets | ||
View ATNM Stock Mentions - Twitter | View ATNM Investment Forum News - Investor Hub | ||
View ATNM Stock Mentions - Yahoo! Message Board | View ATNM Stock Mentions - Seeking Alpha |
View Insider Transactions for ATNM - SECform4.com | View Insider Transactions for ATNM - Insider Cow | ||
View ATNM Major Holdings Summary - CNBC | View Insider Disclosure for ATNM - OTC Markets | ||
View Insider Transactions for ATNM - Yahoo! Finance | View Institutional Holdings for ATNM - NASDAQ |
View ATNM Stock Insight & Charts - FinViz.com | View ATNM Investment Charts - StockCharts.com | ||
View ATNM Stock Overview & Charts - BarChart | View ATNM User Generated Charts - Trading View |
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
Posted on Thursday April 18, 2024
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that results from the Phase 3 SIERRA trial of Iomab-B were presented in an oral presentation at the 50th Annual European Bone Marrow Transplant Society Meeting (EBMT) held in Glasgow, Scotland on April 14-17. The results showed that an Iomab-B led bone marrow transplant (BMT) results in higher rates
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
Posted on Monday April 15, 2024
The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 biotech stocks. Imagine you acquired shares of a popular, richly priced enterprise, only for the underlying security to suffer due to a poor clinical result. And poor results can happen to anybody, big or small. Indeed, the prospect of being on the wrong end of a giant killing adds significant risk to market participants. So, as a calculated approach, since you’re going to be tak
Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual Meeting
Posted on Monday April 01, 2024
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that results from the Phase 3 SIERRA trial of Iomab-B in patients with a TP53 mutation have been accepted for oral presentation at the 50th Annual meeting of the European Bone Marrow Transplant Society (EBMT) being held April 14 – 17, 2024, in Glasgow, Scotland. Iomab-B is a targeted radiotherapy con
Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
Posted on Tuesday March 26, 2024
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that the University of Texas Southwestern Medical Center (UT Southwestern) will lead a clinical trial studying Actinium's Iomab-ACT, a targeted radiotherapy conditioning agent prior to patients receiving an FDA approved commercial CAR T-cell therapy. UT Southwestern will start recruiting patients fol